743 related articles for article (PubMed ID: 28780701)
1. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
4. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
[TBL] [Abstract][Full Text] [Related]
5. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
Qin T; Xu X; Zhang Z; Li J; You X; Guo H; Sun H; Liu M; Dai Z; Zhu H
Nanotechnology; 2020 Sep; 31(36):365101. PubMed ID: 32434167
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
12. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
[TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
[TBL] [Abstract][Full Text] [Related]
16. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
18. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
19. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
Fu S; Chen X; Lo HW; Lin J
Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
